Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2− breast cancer: insights and implications

Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2− breast cancer: insights and implications

Abstract Hormone receptor-positive (HR + )/HER2−negative (HER2 − ) breast cancer is the most common subtype, with biomarker-driven therapies improving outcomes. Circulating tumor DNA (ctDNA) analysis enables minimally invasive assessment of somatic alterations to guide therapy. However, assay choice...

Full description

Saved in:
Bibliographic Details
Main Authors: Eva Valentina Klocker, Nina Dobrić, Ricarda Graf, Christine Beichler, Dominik Hlauschek, Christoph Suppan, Lara Pancheri, Daniel Egle, Carmen Albertini, Rupert Bartsch, Angelika Martina Starzer, Philipp Jakob Jost, Gabriel Rinnerthaler, Ellen Heitzer, Nadia Dandachi, Marija Balic
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00805-z
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items